Notes

Slide Show

Outline

1	The effect of pioglitazone
2	Background
3	PROactive Study Objectives
4	PROactive Study Design
5	Summary of PROactive Data from the Total Cohort
6	Subgroup Analysis of Patients with Previous MI
7	Subgroup Analysis of Patients with Previous MI
8	Baseline Data in Patients with Previous MI
9	Baseline Data in Patients with Previous MI
10	Time to Fatal/Non-fatal MI (excluding silent MI)
11	Pre-specified Analyses for Previous MI Subgroup
12	Time to Composite Cardiac Endpoint (Cardiac Death, Non-fatal MI, Coronary Revascularisation or ACS)
13	Time to ACS
14	Exploratory Analyses for Previous MI Subgroup
15	Median Change in Laboratory Data from Baseline to Final Visit
16	Serious Adverse Events
17	Summary
18	CARE Subgroup: Major Coronary Events in Patients with Diabetes and Glucose-Intolerant MI (A)
19	CARE Subgroup: Major Coronary Events in Patients with Diabetes and Glucose-Intolerant MI (B)
20	CARE Subgroup: Major Coronary Events in Patients with Diabetes and Glucose-Intolerant MI (C)
21	HPS Subgroup: Major Vascular Events (Major Coronary Events, Stroke and Revascularisation) in Patients with Diabetes (A)
22	HPS Subgroup: Major Vascular Events (Major Coronary Events, Stroke and Revascularisation) in Patients with Diabetes (B)
23	HPS Subgroup: Major Vascular Events (Major Coronary Events, Stroke and Revascularisation) in Patients with Diabetes (C)
24	HPS Subgroup: Major Vascular Events (Major Coronary Events, Stroke and Revascularisation) in Patients with Diabetes (D)
25	Conclusions
26	Acknowledgements